Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Researchers have created a remarkable new map of a key part of our brain, the hypothalamus, that will lead to new ways of ...

Patients were treated with tirzepatide-only for four weeks ... Agouti-related peptide is an endogenous antagonist of the MC4R that works with neuropeptide Y to stimulate appetite, whereas MC4R ...

"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.